Market Overview

Why Immunomedics Is Trading Higher Today


Immunomedics Inc (NASDAQ: IMMU) shares are trading higher on Tuesday, after Barclays initiated coverage on the company's stock with an Overweight rating and $40 price target.

Immunomedics is a clinical-stage biopharmaceutical company, based in the U.S. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others.

Immunomedics shares trading up 3.63% at $6.57 on Tuesday. The stock has a 52-week range between $8.92 and $3.26.

Related Links:

Roche's Faster Coronavirus Test Receives FDA Emergency Use Authorization

Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19

Latest Ratings for IMMU

Sep 2020JefferiesDowngradesBuyHold
Sep 2020Wells FargoDowngradesOverweightEqual-Weight
Sep 2020HC Wainwright & Co.DowngradesBuyNeutral

View More Analyst Ratings for IMMU
View the Latest Analyst Ratings


Related Articles (IMMU)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Price Target Initiation Analyst Ratings

Latest Ratings

WWEEvercore ISI GroupUpgrades
INTB of A SecuritiesUpgrades40.0
BLDPBMO CapitalInitiates Coverage On39.0
SSYSStifelInitiates Coverage On40.0
CMGGoldman SachsInitiates Coverage On1,650.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at